questionsmedicales.fr
Acides nucléiques, nucléotides et nucléosides
Nucléotides
Ribonucléotides
Nucléotides uridyliques
Uridine diphosphate
Uridine diphosphate : Questions médicales fréquentes
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate : Questions médicales les plus fréquentes",
"headline": "Uridine diphosphate : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Uridine diphosphate : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-22",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Nucléotides uridyliques",
"url": "https://questionsmedicales.fr/mesh/D014500",
"about": {
"@type": "MedicalCondition",
"name": "Nucléotides uridyliques",
"code": {
"@type": "MedicalCode",
"code": "D014500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate ose",
"alternateName": "Uridine Diphosphate Sugars",
"url": "https://questionsmedicales.fr/mesh/D014539",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate ose",
"code": {
"@type": "MedicalCode",
"code": "D014539",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylgalactosamine",
"alternateName": "Uridine Diphosphate N-Acetylgalactosamine",
"url": "https://questionsmedicales.fr/mesh/D014536",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylgalactosamine",
"code": {
"@type": "MedicalCode",
"code": "D014536",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylglucosamine",
"alternateName": "Uridine Diphosphate N-Acetylglucosamine",
"url": "https://questionsmedicales.fr/mesh/D014537",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylglucosamine",
"code": {
"@type": "MedicalCode",
"code": "D014537",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.120"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate N-acétylmuramique",
"alternateName": "Uridine Diphosphate N-Acetylmuramic Acid",
"url": "https://questionsmedicales.fr/mesh/D014538",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate N-acétylmuramique",
"code": {
"@type": "MedicalCode",
"code": "D014538",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate galactose",
"alternateName": "Uridine Diphosphate Galactose",
"url": "https://questionsmedicales.fr/mesh/D014531",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate galactose",
"code": {
"@type": "MedicalCode",
"code": "D014531",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate glucose",
"alternateName": "Uridine Diphosphate Glucose",
"url": "https://questionsmedicales.fr/mesh/D014532",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate glucose",
"code": {
"@type": "MedicalCode",
"code": "D014532",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate glucuronique",
"alternateName": "Uridine Diphosphate Glucuronic Acid",
"url": "https://questionsmedicales.fr/mesh/D014535",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate glucuronique",
"code": {
"@type": "MedicalCode",
"code": "D014535",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate xylose",
"alternateName": "Uridine Diphosphate Xylose",
"url": "https://questionsmedicales.fr/mesh/D014540",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate xylose",
"code": {
"@type": "MedicalCode",
"code": "D014540",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.800"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate",
"alternateName": "Uridine Diphosphate",
"code": {
"@type": "MedicalCode",
"code": "D014530",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Takayuki Matsumoto",
"url": "https://questionsmedicales.fr/author/Takayuki%20Matsumoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Kumiko Taguchi",
"url": "https://questionsmedicales.fr/author/Kumiko%20Taguchi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan."
}
},
{
"@type": "Person",
"name": "Tsuneo Kobayashi",
"url": "https://questionsmedicales.fr/author/Tsuneo%20Kobayashi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Rafal Jonczyk",
"url": "https://questionsmedicales.fr/author/Rafal%20Jonczyk",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
},
{
"@type": "Person",
"name": "Thomas Hoffmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Hoffmann",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Global varicella vaccination programs.",
"datePublished": "2022-11-02",
"url": "https://questionsmedicales.fr/article/36457198",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3345/cep.2021.01564"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pulling Forces Differentially Affect Refolding Pathways Due to Entangled Misfolded States in SARS-CoV-1 and SARS-CoV-2 Receptor Binding Domain.",
"datePublished": "2024-10-18",
"url": "https://questionsmedicales.fr/article/39456260",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/biom14101327"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.",
"datePublished": "2024-08-23",
"url": "https://questionsmedicales.fr/article/39177691",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00125-024-06251-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "The GLP-1 receptor agonist exendin-4 reduces taurine and glycine in nucleus accumbens of male rats, an effect tentatively involving the nucleus tractus solitarius.",
"datePublished": "2024-08-16",
"url": "https://questionsmedicales.fr/article/39221138",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fphar.2024.1439203"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.",
"datePublished": "2024-07-08",
"url": "https://questionsmedicales.fr/article/38991584",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2213-8587(24)00155-4"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides nucléiques, nucléotides et nucléosides",
"item": "https://questionsmedicales.fr/mesh/D009706"
},
{
"@type": "ListItem",
"position": 3,
"name": "Nucléotides",
"item": "https://questionsmedicales.fr/mesh/D009711"
},
{
"@type": "ListItem",
"position": 4,
"name": "Ribonucléotides",
"item": "https://questionsmedicales.fr/mesh/D012265"
},
{
"@type": "ListItem",
"position": 5,
"name": "Nucléotides uridyliques",
"item": "https://questionsmedicales.fr/mesh/D014500"
},
{
"@type": "ListItem",
"position": 6,
"name": "Uridine diphosphate",
"item": "https://questionsmedicales.fr/mesh/D014530"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Uridine diphosphate - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Uridine diphosphate",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Uridine diphosphate",
"description": "Comment diagnostiquer une carence en UDP ?\nQuels tests sont utilisés pour évaluer l'UDP ?\nL'UDP peut-il être mesuré dans le sang ?\nQuels symptômes indiquent un problème d'UDP ?\nY a-t-il des marqueurs spécifiques pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Uridine diphosphate",
"description": "Quels sont les symptômes d'une carence en UDP ?\nL'UDP affecte-t-il le système nerveux ?\nDes douleurs musculaires peuvent-elles être liées à l'UDP ?\nL'UDP influence-t-il l'humeur ?\nY a-t-il des signes cutanés associés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Uridine diphosphate",
"description": "Comment prévenir une carence en UDP ?\nLes suppléments sont-ils nécessaires pour l'UDP ?\nY a-t-il des groupes à risque pour l'UDP ?\nLes habitudes de vie influencent-elles l'UDP ?\nDes conseils nutritionnels existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Uridine diphosphate",
"description": "Comment traiter une carence en UDP ?\nLes médicaments peuvent-ils aider à l'UDP ?\nY a-t-il des thérapies alternatives pour l'UDP ?\nLes changements alimentaires sont-ils efficaces ?\nDes traitements spécifiques existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Uridine diphosphate",
"description": "Quelles complications peuvent survenir avec une carence en UDP ?\nL'UDP peut-il affecter le développement ?\nDes maladies chroniques sont-elles liées à l'UDP ?\nL'UDP est-il impliqué dans des maladies héréditaires ?\nDes troubles immunitaires peuvent-ils être liés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Uridine diphosphate",
"description": "Quels sont les facteurs de risque pour l'UDP ?\nL'âge influence-t-il les niveaux d'UDP ?\nLe stress peut-il affecter l'UDP ?\nLes maladies génétiques influencent-elles l'UDP ?\nLes habitudes alimentaires jouent-elles un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en UDP ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant les niveaux d'UDP dans les cellules peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'UDP ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests enzymatiques et chromatographiques sont couramment utilisés pour évaluer l'UDP."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il être mesuré dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'UDP est généralement mesuré dans les tissus plutôt que dans le sang en raison de sa faible concentration."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème d'UDP ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des troubles neurologiques ou des anomalies métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour l'UDP ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de marqueurs spécifiques, mais des niveaux d'enzymes peuvent indiquer des anomalies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en UDP ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles cognitifs."
}
},
{
"@type": "Question",
"name": "L'UDP affecte-t-il le système nerveux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut entraîner des troubles neurologiques et cognitifs."
}
},
{
"@type": "Question",
"name": "Des douleurs musculaires peuvent-elles être liées à l'UDP ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "L'UDP influence-t-il l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affecter l'humeur et entraîner des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à l'UDP ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître, mais elles sont moins fréquentes."
}
},
{
"@type": "Question",
"name": "Comment prévenir une carence en UDP ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en acides nucléiques peut aider à prévenir une carence."
}
},
{
"@type": "Question",
"name": "Les suppléments sont-ils nécessaires pour l'UDP ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les suppléments peuvent être bénéfiques, surtout en cas de régime alimentaire pauvre."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque pour l'UDP ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant des troubles métaboliques ou des régimes restrictifs sont à risque."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles l'UDP ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines, comme l'exercice, peuvent soutenir le métabolisme de l'UDP."
}
},
{
"@type": "Question",
"name": "Des conseils nutritionnels existent-ils pour l'UDP ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, consulter un nutritionniste peut aider à élaborer un plan alimentaire adapté."
}
},
{
"@type": "Question",
"name": "Comment traiter une carence en UDP ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments d'uridine et des modifications alimentaires."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à l'UDP ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent améliorer le métabolisme de l'UDP, mais nécessitent une prescription."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies alternatives pour l'UDP ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies comme la nutrition ciblée peuvent être bénéfiques, mais nécessitent des études."
}
},
{
"@type": "Question",
"name": "Les changements alimentaires sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en acides nucléiques peut aider à augmenter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des traitements spécifiques existent-ils pour l'UDP ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques approuvés pour les troubles liés à l'UDP."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une carence en UDP ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et métaboliques peuvent survenir si non traitées."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il affecter le développement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut nuire au développement cognitif et physique chez les enfants."
}
},
{
"@type": "Question",
"name": "Des maladies chroniques sont-elles liées à l'UDP ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies métaboliques chroniques peuvent être exacerbées par une carence en UDP."
}
},
{
"@type": "Question",
"name": "L'UDP est-il impliqué dans des maladies héréditaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles héréditaires du métabolisme peuvent affecter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des troubles immunitaires peuvent-ils être liés à l'UDP ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affaiblir le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'UDP ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les régimes alimentaires pauvres, les maladies métaboliques et le stress sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux d'UDP ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux d'UDP peuvent diminuer avec l'âge, augmentant le risque de carence."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter l'UDP ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber le métabolisme de l'UDP et entraîner des carences."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques influencent-elles l'UDP ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques peuvent affecter la synthèse et l'utilisation de l'UDP."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires jouent-elles un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut augmenter le risque de carence en UDP."
}
}
]
}
]
}
Varicella (chickenpox) is an infectious disease caused by the highly contagious varicella zoster virus with a secondary attack rate greater than 90%. From this perspective, we aimed to establish the b...
Single-molecule force spectroscopy (SMFS) experiments can monitor protein refolding by applying a small force of a few piconewtons (pN) and slowing down the folding process. Bell theory predicts that ...
We compared the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on renal outcomes in individuals with type 2 diabetes, foc...
This was a multicentre retrospective observational study on new users of diabetes medications. Participant characteristics were assessed before and after propensity score matching. The primary endpoin...
After matching, 5701 participants/group were included. Participants were predominantly male, aged 61 years, with a 10 year duration of diabetes, a baseline HbA...
In individuals with type 2 diabetes, treatment with SGLT2i was associated with better preservation of renal function compared with GLP-1RA, as evidenced by slower decline in eGFR. These findings reinf...
The physiological effects of glucagon-like peptide-1 (GLP-1) are mainly centered on its ability to decrease blood glucose levels and facilitate satiety. Additional physiological functions have been id...
SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are consis...
We conducted a collaborative meta-analysis of trials included in the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium, restricted to participants with diabetes. Treatment effects from ...
Across 12 randomised, double-blind, placebo-controlled trials, 3065 (4·2%) of 73 238 participants with diabetes were using GLP-1 receptor agonists at baseline. SGLT2 inhibitors reduced the risk of maj...
The effects of SGLT2 inhibitors on cardiovascular and kidney outcomes are consistent regardless of the background use of GLP-1 receptor agonists. These findings suggest independent effects of these ev...
National Health and Medical Research Council of Australia and the Ramaciotti Foundation....
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is incretin-based therapy that possessed significant glucose lowering and weight loss properties. The present study aims to analyze the efficacy of G...
A thorough search was carried out on the Cochrane Library, ClinicalTrials.gov, Scopus, and Medline databases until April 3rd, 2024, using a mix of pertinent keywords. This review incorporates randomiz...
A total of eight RCTs were incorporated. The results of our meta-analysis indicated that GLP-1RA therapy was associated with higher odds of regression to normoglycemia (OR 4.80; 95%CI: 3.40-6.77, p < ...
This study indicates that while GLP-1RA is a potent therapeutic agent for prediabetes, its adverse effects are concerning, thereby precluding its recommendation as a prediabetes therapy....
Icanbelimod (formerly CBP-307) is a next-generation S1PR modulator, targeting S1PR...
Participants were randomized 3:1, double-blind, to icanbelimod or placebo in four single-dose cohorts (0.1 mg, 0.25 mg, 0.5 mg [n=8 per cohort], 2.5 mg [n=4]) or for 28-days once-daily treatment in tw...
Icanbelimod exposure increased rapidly and dose-dependently with single and multiple dosing (T...
Icanbelimod was well-tolerated up to 0.5 mg and effectively reduced lymphocyte counts....
ClinicalTrials.gov, identifier NCT02280434.b....
Orforglipron is a novel once-daily oral non-peptide glucagon-like peptide-1 receptor agonist with several recently published randomized controlled trials (RCTs) evaluating its role in diabetes and obe...
A systematic search was conducted in electronic databases to identify RCTs that included individuals with obesity who were administered orforglipron and compared to either a placebo or an active compa...
From 12 initially screened articles, data from three RCTs involving 774 people were analyzed with a follow-up duration of up to 36 weeks. Compared to placebo, patients receiving orforglipron 12 mg/day...
Orforglipron at 24-45 mg/day doses is an effective weight loss medication. The efficacy versus side effect profile suggests that 24-36 mg/day is the most optimal dose for orforglipron as an anti-obesi...
To assess the effects of finerenone and glucagon-like peptide 1 receptor agonists (GLP1-RA) on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM), and the relative card...
We searched PubMed, the Cochrane Library, and Embase from January 1, 2000, to December 30, 2022, to identify randomized controlled trials. The primary outcomes were the composite of nonfatal myocardia...
In total, we identified 11 trials and 73,927 participants, 13,847 (18.7%) in finerenone trials and 60,080 (81.3%) in GLP1-RA trials. Finerenone reduced the risk of MACE by 13% (HR, 0.87; 95% CI, 0.79-...
Finerenone and GLP1-RA lead to a risk reduction in MACE to a similar degree in patients with established atherosclerotic cardiovascular disease. For both drug classes, the effect on lowering the risk ...
This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with sparing on days 2-4 in cisplatin-based chemotherapy....
Patients with malignant solid tumors who were treated with cisplatin (≥50 mg/m²) were randomly assigned (1:1) to receive either DEX on days 1-4 (Arm D4) or DEX on day 1 (Arm D1) plus palonosetron, NK-...
A total of 281 patients were enrolled, 278 of whom were randomly assigned to Arm D4 (n = 139) or Arm D1 (n = 139). In 274 patients were included in the efficacy analysis, the rates of delayed CR in Ar...
DEX-sparing is an alternative option for patients receiving cisplatin; however, this revised administration schedule should be applied on an individual basis after a comprehensive evaluation....
UMIN000032269....